L E Adinolfi1, R Utili, A Tonziello, G Ruggiero. 1. Division of Internal Medicine and Hepatology, Faculty of Medicine, Second University of Naples, Naples, Italy. luigielio.adinolfi@unina2.it
Abstract
BACKGROUND: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non-responders. AIMS: The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C was evaluated. PATIENTS AND METHODS: A total of 114 consecutive patients were randomly divided into three groups with a final 2:2:1 ratio: group A (44 patients) received interferon alfa 2b, 3 million units (MU), three times a week, and oral ribavirin (1000 mg/day); group B (46 patients) received interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A; and group C (24 patients) received interferon and ribavirin as in regimen B, plus oral amantadine hydrochloride (200 mg/day). The duration of treatment was 12 months. RESULTS: The end of treatment response for groups A and B was 25% and 29%, respectively, and for group C, 68% (p<0.005). At the end of one year of follow up, a sustained response was observed for six (25%) patients in group C, one (2%) patient in group A, and two (4%) patients in group B (p<0.002). The triple regimen was well tolerated and did not increase the frequency or severity of side effects. CONCLUSIONS: The study demonstrates that for the treatment of interferonnon-responder hepatitis C patients, the association of interferon-ribavirin has a negligible long term effect whereas a triple regimen including interferon, ribavirin, and amantadine can be an effective and safe treatment.
RCT Entities:
BACKGROUND: Fifty per cent of chronic hepatitis Cpatients are non-responders to interferon. At present, there are no recommended therapeutic options for non-responders. AIMS: The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C was evaluated. PATIENTS AND METHODS: A total of 114 consecutive patients were randomly divided into three groups with a final 2:2:1 ratio: group A (44 patients) received interferon alfa 2b, 3 million units (MU), three times a week, and oral ribavirin (1000 mg/day); group B (46 patients) received interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A; and group C (24 patients) received interferon and ribavirin as in regimen B, plus oral amantadine hydrochloride (200 mg/day). The duration of treatment was 12 months. RESULTS: The end of treatment response for groups A and B was 25% and 29%, respectively, and for group C, 68% (p<0.005). At the end of one year of follow up, a sustained response was observed for six (25%) patients in group C, one (2%) patient in group A, and two (4%) patients in group B (p<0.002). The triple regimen was well tolerated and did not increase the frequency or severity of side effects. CONCLUSIONS: The study demonstrates that for the treatment of interferon non-responder hepatitis C patients, the association of interferon-ribavirin has a negligible long term effect whereas a triple regimen including interferon, ribavirin, and amantadine can be an effective and safe treatment.
Authors: G Saracco; A Ciancio; A Olivero; A Smedile; L Roffi; G Croce; C Colletta; G Cariti; M Andreoni; A Biglino; G Calleri; G Maggi; G F Tappero; P G Orsi; N Terreni; A Macor; A Di Napoli; E Rinaldi; G Ciccone; M Rizzetto Journal: Hepatology Date: 2001-07 Impact factor: 17.425
Authors: Geetanjali Chander; Mark S Sulkowski; Mollie W Jenckes; Michael S Torbenson; H Franklin Herlong; Eric B Bass; Kelly A Gebo Journal: Hepatology Date: 2002-11 Impact factor: 17.425
Authors: S Pol; P Couzigou; M Bourlière; A Abergel; J M Combis; D Larrey; A Tran; J Moussalli; R Poupon; P Berthelot; C Bréchot Journal: J Hepatol Date: 1999-07 Impact factor: 25.083
Authors: C Cammà; M Giunta; L Chemello; A Alberti; H Toyoda; C Trepo; P Marcellin; F Zahm; S Schalm; A Craxì Journal: Hepatology Date: 1999-09 Impact factor: 17.425
Authors: A Mangia; N Minerva; M Annese; G Leandro; M R Villani; R Santoro; V Carretta; D Bacca; A Giangaspero; M Bisceglia; F Ventrella; G Dell'Erba; A Andriulli Journal: Hepatology Date: 2001-04 Impact factor: 17.425
Authors: R Sostegni; V Ghisetti; F Pittaluga; G Marchiaro; G Rocca; E Borghesio; M Rizzetto; G Saracco Journal: Hepatology Date: 1998-08 Impact factor: 17.425
Authors: Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter Journal: Wien Klin Wochenschr Date: 2004-08-31 Impact factor: 1.704
Authors: Jack T Nguyen; Justin D Hoopes; Minh H Le; Donald F Smee; Amy K Patick; Dennis J Faix; Patrick J Blair; Menno D de Jong; Mark N Prichard; Gregory T Went Journal: PLoS One Date: 2010-02-22 Impact factor: 3.240
Authors: Steven K Herrine; Robert S Brown; David E Bernstein; Michael S Ondovik; Ellen Lentz; Helen Te Journal: Dig Dis Sci Date: 2005-04 Impact factor: 3.487